Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminodiphenylmethane SCHEMBL8518249 | 0.87 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| Aminodiphenylmethane SCHEMBL7841 | 0.84 | DPP4 (0.65) | DPP4F2HTR2ATAAR1ADRA2A | |
| Aminodiphenylmethane SCHEMBL2408346 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL11480062 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL11478580 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| Aminodiphenylmethane SCHEMBL8686295 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| Aminodiphenylmethane SCHEMBL9596876 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| Aminodiphenylmethane SCHEMBL6970159 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| Aminodiphenylmethane SCHEMBL1764753 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A | |
| Aminodiphenylmethane SCHEMBL28527476 | 0.81 | DPP4 (0.61) | DPP4F2HTR2ATAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107501294-B | Rapamycin guanidine derivative and purposes | 福建省微生物研究所 | 2019-09-10 | — | — | CN | disclosed |
| CN-104205472-B | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | 三菱化学株式会社 | 2017-04-12 | — | — | CN | disclosed |
| CN-104059173-B | A kind of supported late transition metal catalyst for vinyl polymerization | 中国石油化工股份有限公司 | 2016-09-21 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1246885-A | fluorescent material and use thereof | CIBA SC HOLDING AG (CH) | 2000-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | DPP4 3965/4885F2 4718/4885HTR2A 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.